Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers

同时靶向 HDAC 和 PI3K 以克服去势抵抗性和神经内分泌前列腺癌的表型异质性

阅读：4

作者：Ailin Zhang #, Nathan A Lau #, Alicia Wong, Lisha G Brown, Ilsa M Coleman, Navonil De Sarkar, Dapei Li, Diana C DeLucia, Mark P Labrecque, Holly M Nguyen, Jennifer L Conner, Ruth F Dumpit, Lawrence D True, Daniel W Lin, Eva Corey, Joshi J Alumkal, Peter S Nelson, Colm Morrissey, John K Lee

期刊：

Cancer Research Communications

影响因子：

2.000

时间：

2023

起止号：

2023 Nov 20;3(11):2358-2374.

doi：

10.1158/2767-9764.CRC-23-0250

方法学：

FCM、IF、IHC-P

靶点：

ANDR

研究方向：

信号转导、神经、肿瘤

疾病类型：

前列腺癌

信号通路：

PI3K/Akt

Significance

CRPC is a heterogeneous disease constituting multiple phenotypic subtypes that often co-occur within tumors or across metastases in patients. Existing targeted therapies for CRPC do not take this into account. Here we show that fimepinostat, a dual HDAC1/2 and PI3K/AKT inhibitor investigated clinically in other cancer types but not prostate cancer, may overcome this heterogeneity by effectively inhibiting both ARPC and NEPC subtypes of CRPC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。